"We are fully committed to bringing this breakthrough drug to patients as quickly as possible while backing everything we do ...

MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved ...

MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fintel reports that on September 30, 2024, Rodman & Renshaw initiated coverage of MIRA Pharmaceuticals (NasdaqCM:MIRA) with a ...

Investment analysts at Rodman & Renshaw began coverage on shares of MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) in a research report issued to clients and investors on Monday ...

Fintel reports that on September 30, 2024, Rodman & Renshaw initiated coverage of MIRA Pharmaceuticals (NasdaqCM:MIRA) with a Buy recommendation. As of September 25, 2024, the average one-year ...

MIRA Pharmaceuticals Inc. MIRA shares closed higher Friday following the announcement of promising new preclinical data for its lead development product, Ketamir-2. What To Know: The data ...

Bayer on Tuesday said it had applied for marketing authorization with the European Medicines Agency (EMA) for its menopause ...

Conference presentation delivers preclinical results demonstrating Ketamir-2 achieves 100% reversal of neuropathic pain MIAMI, FL / ACCESSWIRE / September 27, 2024 / MIRA Pharmaceuticals ...